AMD

The researchers conducted a retrospective chart review of patients with typical exudative AMD that had been treated with anti-VEGF therapy injections.

Investigators conducted a cohort study to determine if there is a correlation between intake of nitrate and AMD progression based on previous suggestions that low nitrate levels in the diet may put patients at risk of AMD progression.

The researchers reported that there was no significant difference in the AMD prevalence among the 3 study groups.

According to investigators, the study used curated real-world data from the IRIS Registry to report risk of progression by stage.

The company said the submission follows the FDA acceptance of the ONS-5010 BLA for the treatment of wet AMD, with a PDUFA date of August 29, 2023.

Scientists from the Clear Vision Research Lab at The Australian National University and the Korean biotech company MDimune Inc. hope to turn recent research milestones into potential treatments for AMD.

The company confirms target read-out around the end of 2023 and regulatory submission in Europe in H1 2024. The data will also play an important supporting role in U.S. regulatory submission.

Ophthalmologist discusses the impact of getting older on patients diagnosed with the disease.

Researchers from the Deutsches Zentrum für Neurodegenerative Erkrankungen and the Center for Regenerative Therapies Dresden at TU Dresden have found that visual cells in the human retina may not simply die in some diseases, but are mechanically transported out of the retina beforehand.

Aflibercept and bevacizumab are the two most frequently used therapies for the treatment of wet AMD.

While the advent of anti-VEGF therapies resulted in substantially better outcomes in this patient population, the results can vary substantially among patients.

Mediwhale, an AI diagnostics company, aims for FDA approvals to increase non-invasive, early detection to save lives. Reti-Intelligence uses a simple fundus camera to capture images of the eye, and then within one minute the AI algorithm provides the disease risk assessment.

This December, the Ophthalmology Times® EyeCon 2022 at the JW Marriott Marco Island Beach Resort in Florida will provide attendees with an end-of-year opportunity to meet their continuing medical education requirements. This activity has been approved for 12.50 AMA PRA Category 1 Credits™.

According to the company, the primary safety endpoint was achieved at all timepoints with all doses well-tolerated and no treatment-related our serious adverse events.

According to a study, use is linked to a lower prevalence of age-related macular degeneration in European populations.

According to Apellis Pharmaceuticals, the submission will be a Major Amendment to the NDA, extending the review period by three months with an expected PDUFA target action date in February.

Medicare’s 2023 fee schedule includes cuts in reimbursement, which some groups say could lead to reduced access to care to patients who need it most.

Jay S. Duker, MD, chief operating officer of EyePoint Pharmaceuticals, highlights the Phase 1 and Phase 2 DAVIO clinical trials for EYP-1901 in wet age-related macular degeneration. The company also announced the first patient has been dosed in the Phase 2 PAVIA trial of EYP-1901 for nonproliferative diabetic retinopathy.

Nicole Bajic, MD, and Neel S. Vaidya, MD, MPH, share their insights from when they were at this crossroads. Learn more clinical pearls on topics like this and more at Real World Ophthalmology’s virtual conference, “Top 10 Things I Wish I Knew Sooner,” this Saturday, November 5.

The study is one of the first clinical trials to validate the clinical utility of real-world remote physiologic monitoring using an on-demand vision-as-a-service extension to the specialty retina clinic to enable remote monitoring of patients with chronic diseases such as AMD, diabetic retinopathy, and other retinal conditions.

Lawrence Whittle, Chief Commercial Officer for Verana Health, explains what the significance of imaging data linked with electronic health record data means for patient outcomes.

Replay is launching Eudora, an HSV gene therapy company that will target genetic retinal diseases.

Prevent Blindness offers videos, fact sheets, social media graphics and PowerPoint presentations to help ophthalmologists educate the public on the potential effects diabetes may have on vision.

Scott Walter, MD, an investigator in the TENAYA and LUCERNE trials discusses the year 2 data for the treat-and-extend regimen of faricimab for the treatment of nAMD and DME.

The EyeBuddy app will bring telehealth to eye doctors in the coming months, connecting patients across Bangladesh with ophthalmologists at a major eye-care hospital.